|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
US5262404A
(en)
*
|
1990-02-15 |
1993-11-16 |
The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation |
Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
|
|
CA2063454A1
(en)
|
1990-05-21 |
1991-11-22 |
Masanobu Yoshinaga |
Cyclodextrin derivatives
|
|
JP2556236B2
(ja)
*
|
1991-08-29 |
1996-11-20 |
田辺製薬株式会社 |
β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
|
|
ZA927923B
(en)
*
|
1991-10-16 |
1993-04-26 |
Schering Corp |
Lipophilic oligosaccharide antibiotic salt compositions.
|
|
DE4204315A1
(de)
*
|
1992-02-13 |
1993-08-19 |
Consortium Elektrochem Ind |
Cyclodextringlycoside und verfahren zu ihrer herstellung
|
|
US5403828A
(en)
*
|
1992-08-13 |
1995-04-04 |
American Maize-Products Company |
Purification of cyclodextrin complexes
|
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
DE4309579C3
(de)
*
|
1993-03-24 |
2000-01-27 |
Sanol Arznei Schwarz Gmbh |
Pharmazeutische Zusammensetzung in Form einer Packung
|
|
DE4313408A1
(de)
*
|
1993-04-23 |
1994-10-27 |
Boehringer Mannheim Gmbh |
Cyclodextrin-Biocid-Komplex
|
|
HU213200B
(en)
*
|
1993-05-12 |
1997-03-28 |
Chinoin Gyogyszer Es Vegyeszet |
The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
|
|
ZA949715B
(en)
*
|
1993-12-14 |
1996-06-06 |
Lilly Co Eli |
Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
|
|
US5443824A
(en)
*
|
1994-03-14 |
1995-08-22 |
Piacquadio; Daniel J. |
Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
|
|
DE4429229A1
(de)
*
|
1994-08-18 |
1996-02-22 |
Consortium Elektrochem Ind |
Cyclodextrinderivate mit mindestens einem stickstoffhaltigen Heterozyklus, ihre Herstellung und Verwendung
|
|
EP0709099A3
(de)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
|
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
|
BE1008978A5
(fr)
*
|
1994-12-27 |
1996-10-01 |
Solvay |
Adjuvants pour vaccins.
|
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
|
DE19505263A1
(de)
*
|
1995-02-16 |
1996-08-22 |
Consortium Elektrochem Ind |
Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
|
|
AU5774796A
(en)
*
|
1995-06-13 |
1997-01-09 |
Dyer, Alison Margaret |
Pharmaceutical compositions containing lornoxicam and cyclod extrin
|
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
|
HUT75956A
(en)
*
|
1995-11-29 |
1997-05-28 |
Cyclolab |
Pharmaceutical composition containing thyroxine
|
|
GB9605705D0
(en)
|
1996-03-19 |
1996-05-22 |
Pfizer Ltd |
Therapeutic agents
|
|
ES2243994T5
(es)
|
1996-04-19 |
2009-10-29 |
Grifols Inc. |
Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas.
|
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
|
ATE493983T1
(de)
*
|
1996-11-05 |
2011-01-15 |
Childrens Medical Center |
Thalidomide und dexamethason für die behandlung von tumors
|
|
KR100435426B1
(ko)
*
|
1996-11-29 |
2004-08-16 |
주식회사 포스코 |
구조 이성질체의 분리에 유용한 6-디메틸옥틸실릴-2,3-디에틸-베타-시클로덱스트린 및 그 제조방법
|
|
KR100411289B1
(ko)
*
|
1996-11-29 |
2004-02-14 |
주식회사 포스코 |
회전장애 이성질체의 분리에 유용한 6-알릴디메틸실릴-2,3-디에 틸-베타-시클로덱스트린 및 그 제조방법
|
|
DE19713092A1
(de)
*
|
1997-03-27 |
1998-10-01 |
Wacker Chemie Gmbh |
Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
|
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
|
RU2173172C2
(ru)
*
|
1997-05-05 |
2001-09-10 |
Сайдекс Инк. |
Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента
|
|
US6133248A
(en)
*
|
1997-06-13 |
2000-10-17 |
Cydex, Inc. |
Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
|
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
|
EP0889056B1
(de)
*
|
1997-07-01 |
2006-04-12 |
Pfizer Products Inc. |
Verfahren zur Herstellung von einem Cyclodextrin
|
|
US6391862B1
(en)
*
|
1997-10-14 |
2002-05-21 |
The Texas A&M University System |
Chiral resolving agents for enantioseparations
|
|
EP1067942A1
(de)
*
|
1998-02-23 |
2001-01-17 |
Cyclops, EHF. |
Hochenergetische cyclodextrinkomplexe
|
|
US6699849B1
(en)
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
|
US6048736A
(en)
*
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
|
US6673828B1
(en)
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
|
DE19825486C2
(de)
*
|
1998-06-08 |
2000-07-06 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit supramolekularen Hohlraummolekülen, Verfahren zu deren Herstellung und deren Verwendung
|
|
NZ330726A
(en)
*
|
1998-06-18 |
2000-10-27 |
Dec Res |
Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
|
|
WO2000012137A1
(en)
|
1998-09-02 |
2000-03-09 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
|
US20040152664A1
(en)
*
|
1998-09-02 |
2004-08-05 |
Allergan, Inc. |
Prednisolone compositions
|
|
US20020198174A1
(en)
*
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
|
KR100708360B1
(ko)
*
|
1999-01-21 |
2007-04-17 |
브리스톨-마이어스스퀴브컴파니 |
라스-파르네실트란스퍼라제 억제제와술포부틸에테르-7-β-시클로덱스트린 또는2-히드록시프로필-β-시클로덱스트린과의 착물 및 방법
|
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
|
GB9915231D0
(en)
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
|
DE19939662A1
(de)
|
1999-08-20 |
2001-02-22 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit Hohlraumverbindungen, Verfahren zur deren Herstellung und deren Verwendung
|
|
GB9921958D0
(en)
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
|
|
GB9921954D0
(en)
*
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
|
|
RU2163120C1
(ru)
*
|
1999-10-12 |
2001-02-20 |
Новосибирский медицинский институт |
Конъюгат изониазид-декстран и его применение в качестве противотуберкулезного препарата
|
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
|
US6689378B1
(en)
|
1999-12-28 |
2004-02-10 |
Kimberly-Clark Worldwide, Inc. |
Cyclodextrins covalently bound to polysaccharides
|
|
US6677256B1
(en)
|
1999-12-28 |
2004-01-13 |
Kimberly-Clark Worldwide, Inc. |
Fibrous materials containing activating agents for making superabsorbent polymers
|
|
AU777449C
(en)
*
|
1999-12-28 |
2007-03-15 |
Kimberly-Clark Worldwide, Inc. |
Superabsorbent polymers
|
|
CA2726789A1
(en)
*
|
2000-02-05 |
2001-11-08 |
Theravance, Inc. |
Cyclodextrin containing glycopeptide antibiotic compositions
|
|
SK282717B6
(sk)
*
|
2000-03-10 |
2002-11-06 |
�Stav Experiment�Lnej Farmakol�Gie Sav |
Spôsob prípravy ultravysokomolekulových hyalurónanov
|
|
KR20030003708A
(ko)
*
|
2000-03-31 |
2003-01-10 |
셀진 코포레이션 |
시클로옥시게나제-2 활성의 저해
|
|
BR0110679A
(pt)
*
|
2000-04-28 |
2004-04-20 |
Univ Dublin |
Derivados anfìfilos macrocìclicos e seus análogos
|
|
CN100355753C
(zh)
|
2000-05-26 |
2007-12-19 |
辉瑞大药厂 |
用于制备具有治疗作用的莨菪烷衍生物的中间体
|
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
|
US7198801B2
(en)
*
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
|
US20040198706A1
(en)
*
|
2003-03-11 |
2004-10-07 |
Carrara Dario Norberto R. |
Methods and formulations for transdermal or transmucosal application of active agents
|
|
US20070225379A1
(en)
*
|
2001-08-03 |
2007-09-27 |
Carrara Dario Norberto R |
Transdermal delivery of systemically active central nervous system drugs
|
|
ATE485837T1
(de)
*
|
2000-08-03 |
2010-11-15 |
Antares Pharma Ipl Ag |
Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
|
|
PE20020300A1
(es)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
ATE374609T1
(de)
*
|
2000-11-30 |
2007-10-15 |
Childrens Medical Center |
Synthese von 4-aminothalidomid enantiomeren
|
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
|
RU2288921C2
(ru)
*
|
2000-12-19 |
2006-12-10 |
Калифорниа Инститьют оф Текнолоджи |
Композиции, содержащие комплексы включения
|
|
AU2002241823A1
(en)
|
2001-01-11 |
2002-07-24 |
Eastman Chemical Company |
Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
|
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
|
IL157875A0
(en)
|
2001-04-10 |
2004-03-28 |
Pfizer |
Pyrazole derivatives for treating hiv
|
|
BR0102252B1
(pt)
*
|
2001-04-10 |
2013-10-22 |
|
Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
|
|
JP2004531537A
(ja)
*
|
2001-05-01 |
2004-10-14 |
ファイザー・プロダクツ・インク |
一様な薬剤分布と効力を有する低用量製薬組成物の製造方法
|
|
UY27304A1
(es)
|
2001-05-24 |
2002-12-31 |
Avanir Pharmaceuticals |
Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
EP1269994A3
(de)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
|
JP2005515996A
(ja)
*
|
2001-12-03 |
2005-06-02 |
ノバセア インコーポレイティッド |
活性型ビタミンd化合物を含む薬学的組成物
|
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
|
CN1625397A
(zh)
|
2002-02-01 |
2005-06-08 |
辉瑞产品公司 |
胆固醇酯转移蛋白抑制剂的控制释放药物剂型
|
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
|
MXPA04007737A
(es)
|
2002-02-11 |
2004-10-15 |
Pfizer |
Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4.
|
|
US20030164219A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Joerg Brahm |
Headliner/duct assembly and welding process therefor
|
|
MXPA04008171A
(es)
*
|
2002-02-22 |
2004-11-26 |
Pharmacia Corp |
Formulacion oftalmica con sistema de goma.
|
|
BR0307898A
(pt)
*
|
2002-02-22 |
2004-12-07 |
Pharmacia Corp |
Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
|
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
|
KR100451485B1
(ko)
*
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
|
DE10215942A1
(de)
*
|
2002-04-11 |
2003-10-23 |
Bayer Ag |
Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
|
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
|
US6869939B2
(en)
*
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
CA2752124A1
(en)
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
EP2258363A1
(de)
|
2002-05-17 |
2010-12-08 |
Celgene Corporation |
Zusammensetzungen zur Behandlung von Krebs
|
|
US6818662B2
(en)
*
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
|
ATE428423T1
(de)
*
|
2002-08-20 |
2009-05-15 |
Bristol Myers Squibb Co |
Aripiprazol-komplex-formulierung und verfahren
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US6884790B2
(en)
*
|
2002-09-09 |
2005-04-26 |
Josef Pitha |
Verifiable absorption drug delivery form based on cyclodextrins
|
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
|
RU2359698C2
(ru)
*
|
2002-09-13 |
2009-06-27 |
Сайдекс, Инк. |
Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
|
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
|
US20040053895A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
EP1900369A1
(de)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
|
|
CN1713905A
(zh)
*
|
2002-10-15 |
2005-12-28 |
细胞基因公司 |
用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
|
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US7001893B2
(en)
*
|
2002-10-28 |
2006-02-21 |
Council Of Scientific And Industrial Research |
Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
TW200501945A
(en)
|
2002-11-06 |
2005-01-16 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
|
US20050026877A1
(en)
*
|
2002-12-03 |
2005-02-03 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
|
AU2003303041B2
(en)
|
2002-12-13 |
2008-07-24 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
|
BR0316685A
(pt)
*
|
2002-12-17 |
2005-11-01 |
Nastech Pharm Co |
Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
|
|
US7229966B2
(en)
*
|
2002-12-17 |
2007-06-12 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
|
US7186692B2
(en)
*
|
2002-12-17 |
2007-03-06 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
|
US7166575B2
(en)
*
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
|
JP2006516034A
(ja)
*
|
2003-01-14 |
2006-06-15 |
テバ ファーマシューティカル インダストリーズ リミティド |
全身性エリテマトーデスを治療するためのペプチドの非経口製剤
|
|
KR20050100617A
(ko)
*
|
2003-01-14 |
2005-10-19 |
테바 파마슈티컬 인더스트리즈 리미티드 |
전신 홍반 루푸스 치료용 펩티드의 비 경구 제형
|
|
EP1460064A1
(de)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide als beta-2 Agonisten
|
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
|
US20050020546A1
(en)
*
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
AU2004263830B2
(en)
|
2003-06-13 |
2008-12-18 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
|
EP1663220B1
(de)
|
2003-09-03 |
2009-12-02 |
Glaxo Group Limited |
Neues verfahren zur herstellung von pleuromutilinderivaten
|
|
UA86204C2
(uk)
|
2003-09-03 |
2009-04-10 |
Пфайзер Инк. |
Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність
|
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
|
WO2005023308A1
(en)
*
|
2003-09-05 |
2005-03-17 |
Maxygen Holdings Ltd. |
Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
|
|
AU2004271800A1
(en)
|
2003-09-12 |
2005-03-24 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
|
KR100777885B1
(ko)
|
2003-10-03 |
2007-11-28 |
화이자 인코포레이티드 |
Hiv 및 염증 치료를 위한 ccr5 수용체 길항제 활성을갖는 이미다조피리딘 치환된 트로판 유도체
|
|
ATE534373T1
(de)
|
2003-10-10 |
2011-12-15 |
Antares Pharma Ipl Ag |
Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
|
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
|
KR20060124607A
(ko)
*
|
2003-11-06 |
2006-12-05 |
셀진 코포레이션 |
암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
|
|
DE602004031356D1
(de)
|
2003-11-21 |
2011-03-24 |
Zalicus Inc |
Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
|
|
WO2005055952A2
(en)
*
|
2003-12-08 |
2005-06-23 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Synergistic anti-cancer compositions
|
|
PL1691811T3
(pl)
|
2003-12-11 |
2014-12-31 |
Sunovion Pharmaceuticals Inc |
Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
|
|
AU2004311478A1
(en)
*
|
2003-12-31 |
2005-07-21 |
Cydex Pharmaceuticals, Inc. |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
|
US20070020299A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
BRPI0506994A
(pt)
|
2004-01-22 |
2007-07-03 |
Pfizer |
derivados de triazol que inibem a atividade antagonista da vasopressina
|
|
PL1708991T3
(pl)
|
2004-01-22 |
2008-02-29 |
Pfizer |
Pochodne sulfonoamidu do leczenia chorób
|
|
KR100785580B1
(ko)
|
2004-01-22 |
2007-12-13 |
화이자 인코포레이티드 |
질환 치료용 술폰아미드 유도체
|
|
EP2388017B1
(de)
|
2004-02-24 |
2014-12-24 |
The General Hospital Corporation |
Katalytische Radiofluorierung
|
|
WO2005088655A1
(en)
*
|
2004-03-12 |
2005-09-22 |
The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
A magnetoresistive medium
|
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
|
AU2005223483B2
(en)
|
2004-03-18 |
2009-04-23 |
Zoetis Llc |
N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
|
|
CA2560221C
(en)
*
|
2004-03-22 |
2010-12-07 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
|
EP1730103B1
(de)
|
2004-03-23 |
2010-05-26 |
Pfizer Limited |
Als adrenozeptor geeignete formamidderivate
|
|
AU2004319758A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
|
US20080213213A1
(en)
*
|
2004-04-14 |
2008-09-04 |
Zeldis Jerome B |
Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
|
|
US8129346B2
(en)
|
2004-04-15 |
2012-03-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
|
CN101098678A
(zh)
|
2004-04-23 |
2008-01-02 |
锡德克斯公司 |
含有磺基烷基醚环糊精的dpi制剂
|
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
|
JP4185154B2
(ja)
|
2004-04-30 |
2008-11-26 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
中枢神経系障害治療用の置換モルホリン化合物
|
|
MXPA06012777A
(es)
*
|
2004-05-06 |
2007-02-14 |
Cydex Inc |
Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
|
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
|
EP2030981B1
(de)
*
|
2004-05-10 |
2014-07-09 |
Onyx Therapeutics, Inc. |
Verbindungen zur Proteasome Enzymhemmung
|
|
EP1595881A1
(de)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
|
|
CA2569654C
(en)
|
2004-06-15 |
2010-12-21 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
|
WO2006007412A2
(en)
*
|
2004-06-16 |
2006-01-19 |
Nastech Pharmaceutical Company Inc. |
Peptide yy formulations having increased stability and resistance to microbial agents
|
|
MXPA06014754A
(es)
|
2004-06-17 |
2007-06-22 |
Infinity Pharmaceuticals Inc |
Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
|
|
EA012119B1
(ru)
|
2004-08-12 |
2009-08-28 |
Пфайзер Инк. |
ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
|
|
DE602005020465D1
(de)
|
2004-08-26 |
2010-05-20 |
Pfizer |
Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
|
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
|
EP1797068B1
(de)
*
|
2004-09-03 |
2013-10-09 |
Celgene Corporation |
Verfahren zur herstellung substituierter 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline
|
|
EP2436680B1
(de)
|
2004-09-21 |
2016-05-18 |
Marshall Edwards, Inc. |
Chromanderivate, Medikamente und Anwendung in der Therapie
|
|
CA2581316C
(en)
|
2004-09-21 |
2013-09-10 |
Novogen Research Pty Ltd |
Substituted chroman derivatives, medicaments and use in therapy
|
|
US8080675B2
(en)
|
2004-09-21 |
2011-12-20 |
Marshall Edwards, Inc. |
Chroman derivatives, medicaments and use in therapy
|
|
US20060078955A1
(en)
*
|
2004-10-13 |
2006-04-13 |
Lin-Zhi International |
Method for retrieving delta9-THC from oral fluid
|
|
GEP20084424B
(en)
*
|
2004-10-26 |
2008-07-10 |
Viktor Rybchuk |
Sedative and spasmolytic medicinal agent and method for the production thereof (variants)
|
|
WO2006050057A2
(en)
*
|
2004-10-28 |
2006-05-11 |
Celgene Corporation |
Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
|
|
ES2318556T3
(es)
|
2004-11-02 |
2009-05-01 |
Pfizer, Inc. |
Derivados de sulfonil bencimidazol.
|
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
|
WO2006052921A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Eastman Chemical Company |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
|
US20060105992A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
|
PT2260835E
(pt)
*
|
2004-12-07 |
2013-05-28 |
Onyx Therapeutics Inc |
Composição para inibição do proteassoma
|
|
US20060128654A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20060128653A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
|
DE102004060927B3
(de)
*
|
2004-12-17 |
2006-02-16 |
Schwan-Stabilo Schwanhäusser Gmbh & Co. Kg |
Behälter für mindestens einen länglichen Gegenstand
|
|
EP1674098A1
(de)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
|
|
JP2008530230A
(ja)
*
|
2005-02-16 |
2008-08-07 |
アルザ・コーポレーシヨン |
エリスロポエチンに基づく剤の経皮送達のための装置および方法
|
|
EA200701752A1
(ru)
*
|
2005-02-18 |
2008-04-28 |
Сурфейс Логикс Инк. |
Способ получения усовершенствованных фармакокинетических соединений, включающих функциональные остатки или группы, и фармацевтические композиции, содержащие эти соединения
|
|
CN102351862A
(zh)
*
|
2005-02-18 |
2012-02-15 |
表面线段公司 |
药动学改善的化合物
|
|
CA2614223A1
(en)
|
2005-02-24 |
2006-08-31 |
Dr Pharma Nova, Llc |
A registry method and control system for dea schedule ii-v medicines
|
|
EA200701745A1
(ru)
|
2005-03-17 |
2008-06-30 |
Пфайзер, Инк. |
Циклопропанкарбоксамидные производные
|
|
EP1863795B1
(de)
|
2005-03-21 |
2008-10-29 |
Pfizer Limited |
Substituierte triazolderivate als oxytocinantagonisten
|
|
EP2484382A1
(de)
|
2005-03-30 |
2012-08-08 |
Schering Corporation |
Medikament enthaltend einem Phosphodiesterase IV Inhibitor in einer zur Inhalation geeigneten Form
|
|
CA2603785C
(en)
*
|
2005-04-15 |
2014-07-22 |
Roman Perez-Soler |
Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
|
|
ES2525096T3
(es)
|
2005-04-19 |
2014-12-17 |
Kings College London |
Uso de bip contra la pérdida ósea y osteoporosis
|
|
US20060258712A1
(en)
*
|
2005-04-24 |
2006-11-16 |
Wyeth |
Methods for modulating bladder function
|
|
AU2006242920A1
(en)
|
2005-05-04 |
2006-11-09 |
Pfizer Limited |
2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
|
|
US8669236B2
(en)
*
|
2005-05-12 |
2014-03-11 |
The General Hospital Corporation |
Biotinylated compositions
|
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
|
US8067399B2
(en)
|
2005-05-27 |
2011-11-29 |
Antares Pharma Ipl Ag |
Method and apparatus for transdermal or transmucosal application of testosterone
|
|
MX2007015862A
(es)
*
|
2005-06-13 |
2008-02-22 |
Cargill Inc |
Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.
|
|
MX2007015871A
(es)
*
|
2005-06-13 |
2008-03-04 |
Cargill Inc |
Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.
|
|
CA2611917A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Takeda Pharmaceutical Company Limited |
Injection
|
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
|
CN101228134A
(zh)
|
2005-06-15 |
2008-07-23 |
辉瑞有限公司 |
用作杀寄生虫剂的取代芳基吡唑
|
|
US20060287301A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mcnair Douglas |
Novel formulations for phenothiazines, including fluphenazine and its derivatives
|
|
MX2007016290A
(es)
|
2005-06-30 |
2008-03-10 |
Celgene Corp |
Procesos para la preparacion de compuestos de 4-amino-2(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona.
|
|
US20070010478A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
|
|
AU2006269498A1
(en)
*
|
2005-07-06 |
2007-01-18 |
Edgar, Mark |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070010486A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070010485A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070010487A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070009531A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
|
|
AR054849A1
(es)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
|
UA91560C2
(ru)
|
2005-08-31 |
2010-08-10 |
Селджин Корпорэйшн |
Соединения ряда изоиндолимидов, их композиция и применение
|
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
|
US7744904B1
(en)
*
|
2005-09-26 |
2010-06-29 |
B.B. Scientific L.L.C. |
Stabilization of Clostridium botulinum neurotoxin complex
|
|
AU2013200204B9
(en)
*
|
2005-09-30 |
2015-03-05 |
Lundbeck Llc |
Novel parenteral carbamazepine formulation
|
|
US20100204178A1
(en)
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
|
BRPI0616447A2
(pt)
*
|
2005-09-30 |
2011-06-21 |
Ovation Pharmaceuticals Inc |
complexo de inclusão de carbamazepina-ciclodextrina, método de administrar e método de preparar o mesmo
|
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
|
AU2011204957B2
(en)
*
|
2005-10-26 |
2013-12-05 |
Cydex Pharmaceuticals, Inc |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
|
RU2417103C2
(ru)
*
|
2005-10-26 |
2011-04-27 |
Сайдекс Фармасьютикалз, Инк. |
Композиции простого сульфоалкилового эфира циклодекстрина и способы их получения
|
|
PT2583668E
(pt)
|
2005-10-26 |
2015-01-05 |
Cydex Pharmaceuticals Inc |
Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
|
|
CN100503647C
(zh)
|
2005-11-02 |
2009-06-24 |
南京师范大学 |
羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
|
|
MY171061A
(en)
*
|
2005-11-09 |
2019-09-24 |
Onyx Therapeutics Inc |
Compounds for enzyme inhibition
|
|
US20070111965A1
(en)
*
|
2005-11-15 |
2007-05-17 |
Kipp James E |
Compositions comprising lipoxygenase inhibitors and cyclodextrin
|
|
US7658913B2
(en)
*
|
2005-11-28 |
2010-02-09 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
|
US7858609B2
(en)
|
2005-11-28 |
2010-12-28 |
Marinus Pharmaceuticals |
Solid ganaxolone formulations and methods for the making and use thereof
|
|
NZ592293A
(en)
*
|
2005-11-28 |
2012-10-26 |
Verrow Pharmaceuticals Inc |
Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs
|
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
|
US20070232537A1
(en)
*
|
2005-12-19 |
2007-10-04 |
Nastech Pharmaceutical Company Inc. |
Intranasal pyy formulations with improved transmucosal pharmacokinetics
|
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
|
JP2009526858A
(ja)
*
|
2006-02-15 |
2009-07-23 |
ティカ レーケメデル アーベー |
コルチコステロイド溶液を製造する方法
|
|
EP1998773A2
(de)
*
|
2006-03-24 |
2008-12-10 |
Wyeth a Corporation of the State of Delaware |
Neue therapeutische kombinationen zur behandlung von depression
|
|
JP2009531436A
(ja)
*
|
2006-03-24 |
2009-09-03 |
ワイス |
認知障害および他の障害の治療方法
|
|
AR060324A1
(es)
*
|
2006-03-24 |
2008-06-11 |
Wyeth Corp |
Metodos para modular la funcion de la vejiga
|
|
AU2007230997A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Treatment of pain
|
|
US20070225278A1
(en)
*
|
2006-03-24 |
2007-09-27 |
Wyeth |
Methods for treating cognitive and other disorders
|
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
|
MX2008013405A
(es)
|
2006-04-18 |
2009-03-09 |
Ekr Therapeutics Inc |
Composiciones farmaceuticas premezcladas listas para uso.
|
|
CN101426475A
(zh)
*
|
2006-04-21 |
2009-05-06 |
安塔雷斯制药Ipl股份公司 |
使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
|
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
CN100374468C
(zh)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
水溶性磺烷基醚-β-环糊精的合成工艺
|
|
AU2007258280B2
(en)
|
2006-06-12 |
2013-05-02 |
Sunesis Pharmaceuticals, Inc. |
Compounds and compositions for treatment of cancer
|
|
JP2009539978A
(ja)
*
|
2006-06-13 |
2009-11-19 |
カーギル インコーポレイテッド |
大粒子シクロデキストリン包接複合体及びその製造方法
|
|
CA2657213C
(en)
|
2006-06-19 |
2017-01-03 |
Proteolix, Inc. |
Peptide epoxyketones for proteasome inhibition
|
|
EP2043685B1
(de)
*
|
2006-07-03 |
2015-12-23 |
Genmab A/S |
Prävention von hautausschlag bei patienten in anti-egfr-therapie
|
|
AR061889A1
(es)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
Proceso mejorado para la preparacion de voriconazol
|
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
|
DK2049109T3
(en)
|
2006-08-02 |
2016-01-11 |
Sunesis Pharmaceuticals Inc |
Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
|
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
KR101403887B1
(ko)
|
2006-08-03 |
2014-06-20 |
트러스티즈 오브 터프츠 칼리지 |
홍조화를 유발하지 않는 니아신 유사체, 및 이의 사용 방법
|
|
WO2008024914A2
(en)
|
2006-08-23 |
2008-02-28 |
Intellect Neurosciences Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CN100486645C
(zh)
*
|
2006-09-12 |
2009-05-13 |
南京师范大学 |
含有环糊精紫杉醇包合物的药物组合物及其制备方法
|
|
CA2664251A1
(en)
|
2006-09-12 |
2008-03-20 |
Cephalin Pharmaceuticals Inc. |
Isovaline for treatment of pain
|
|
CN100411688C
(zh)
*
|
2006-09-12 |
2008-08-20 |
南京师范大学 |
含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
|
|
EP2061458B1
(de)
*
|
2006-09-15 |
2014-12-10 |
Regents of the University of Minnesota |
Topiramatzubereitungen und verfahren zu ihrer verwendung
|
|
US20090239942A1
(en)
*
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
|
US20100093861A1
(en)
|
2006-09-15 |
2010-04-15 |
Stevia Aps |
Treatment of insulin resistance or diseases associated with insulin resistance
|
|
JP5140080B2
(ja)
|
2006-09-21 |
2013-02-06 |
ラクオリア創薬株式会社 |
選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体
|
|
ME02420B
(me)
|
2006-09-26 |
2016-09-20 |
Celgene Corp |
5-supstituirani derivati kinazolinona kao sredstva protiv raka
|
|
EP2076287A2
(de)
|
2006-10-12 |
2009-07-08 |
Wyeth |
Verfahren und zusammensetzungen mit verringerter opaleszenz
|
|
DE602007011793D1
(de)
|
2006-10-18 |
2011-02-17 |
Pfizer Prod Inc |
Biaryl-ether-harnstoffverbindungen
|
|
ATE520651T1
(de)
|
2006-10-23 |
2011-09-15 |
Pfizer |
Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
|
|
ES2541546T3
(es)
|
2006-11-03 |
2015-07-21 |
Wyeth Llc |
Sustancias que inhiben la glucólisis en cultivo celular
|
|
PL2094308T3
(pl)
*
|
2006-11-21 |
2011-06-30 |
Novartis Ag |
Trwały preparat pozajelitowy zawierający inhibitor RSV o strukturze benzodiazepiny
|
|
WO2008065142A1
(en)
*
|
2006-11-29 |
2008-06-05 |
N.V. Organon |
Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
|
|
WO2008067991A2
(en)
*
|
2006-12-08 |
2008-06-12 |
Antares Pharma Ipl Ag |
Skin-friendly drug complexes for transdermal administration
|
|
EP2049083A2
(de)
*
|
2006-12-27 |
2009-04-22 |
Cargill, Incorporated |
Cyclodextrin-einschlusskomplexe und verfahren zu ihrer herstellung
|
|
AU2008223133A1
(en)
|
2007-03-02 |
2008-09-12 |
Wyeth |
Use of copper and glutamate in cell culture for production of polypeptides
|
|
EP2131849B1
(de)
*
|
2007-03-02 |
2011-10-26 |
The University Of Wollongong |
Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
|
|
WO2011084703A2
(en)
|
2009-12-21 |
2011-07-14 |
Advanced Liquid Logic, Inc. |
Enzyme assays on a droplet actuator
|
|
JP5681485B2
(ja)
*
|
2007-04-27 |
2015-03-11 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法
|
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
|
US20080283693A1
(en)
*
|
2007-05-15 |
2008-11-20 |
Evans Michael J F |
Propulsion apparatus and system
|
|
TWI364290B
(en)
|
2007-05-25 |
2012-05-21 |
Ipsen Pharma Sas |
Melanocortin receptor ligands modifled with hydantoin
|
|
US12370352B2
(en)
|
2007-06-28 |
2025-07-29 |
Cydex Pharmaceuticals, Inc. |
Nasal and ophthalmic delivery of aqueous corticosteroid solutions
|
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
|
TWI428132B
(zh)
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
癌症化療效果之強化
|
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
|
US20090082400A1
(en)
*
|
2007-07-31 |
2009-03-26 |
Ving Lee |
Soluble pyrone analogs methods and compositions
|
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
|
BRPI0816278A2
(pt)
|
2007-09-05 |
2015-09-22 |
Pfizer Ltd |
forma sal
|
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
|
CA2704710C
(en)
|
2007-09-26 |
2016-02-02 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
|
|
KR20170125413A
(ko)
|
2007-10-04 |
2017-11-14 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
|
EP2214662B1
(de)
*
|
2007-10-22 |
2016-07-13 |
Sunesis Pharmaceuticals, Inc. |
(+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridin-3-carbonsäure in der kombinationstherapie mit gemcitabin zur behandlung von krebs
|
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
|
EP2252291A1
(de)
*
|
2008-02-28 |
2010-11-24 |
Takeda Pharmaceutical Company Limited |
Pharmazeutische zusammensetzung
|
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
|
EP2259793A2
(de)
*
|
2008-04-30 |
2010-12-15 |
Neutron Row |
Verwendung eines corticotropin freisetzenden faktors zur krebsbehandlung
|
|
US20110224232A1
(en)
*
|
2008-05-06 |
2011-09-15 |
Board Of Regents, The University Of Texas System |
Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
|
|
US20110144202A1
(en)
*
|
2008-06-16 |
2011-06-16 |
Uwe Marx |
Concentrated oxaliplatin solution and its method of preparation
|
|
WO2010014617A1
(en)
*
|
2008-07-28 |
2010-02-04 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
|
JP5576370B2
(ja)
|
2008-08-06 |
2014-08-20 |
ファイザー・インク |
Chk−1阻害剤としての6置換2−ヘテロシクリルアミノピラジン化合物
|
|
WO2010022467A1
(en)
|
2008-08-29 |
2010-03-04 |
Novogen Research Pty Ltd |
Immunomodulating activities
|
|
EP2163253B1
(de)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
|
|
EP3090737A1
(de)
|
2008-10-21 |
2016-11-09 |
Onyx Therapeutics, Inc. |
Kombinationstherapie mit peptidepoxyketonen
|
|
US20100130598A1
(en)
*
|
2008-10-22 |
2010-05-27 |
Novogen Research Pty Ltd. |
Methods for inducing programmed cell death
|
|
BR122020021379B1
(pt)
|
2008-10-24 |
2021-05-11 |
Sarepta Therapeutics, Inc. |
oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
|
|
PT2358697E
(pt)
|
2008-10-29 |
2016-02-03 |
Celgene Corp |
Compostos de isoindolina para utilização no tratamento do cancro
|
|
US10463677B2
(en)
|
2008-11-07 |
2019-11-05 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
|
AU2009314072C1
(en)
*
|
2008-11-15 |
2016-11-10 |
Melinta Subsidiary Corp. |
Antimicrobial compositions
|
|
MX2011005221A
(es)
|
2008-11-21 |
2011-08-03 |
Raqualia Pharma Inc |
Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b.
|
|
CN105384676B
(zh)
|
2008-12-16 |
2019-05-07 |
桑诺维恩药品公司 |
三重再摄取抑制剂及其应用方法
|
|
KR20110101212A
(ko)
|
2008-12-17 |
2011-09-15 |
제넨테크, 인크. |
C형 간염 바이러스 조합 요법
|
|
KR20170090535A
(ko)
|
2008-12-31 |
2017-08-07 |
선에시스 파마슈티컬스 인코포레이티드 |
(+)-1,4-다이하이드로-7-[(3s,4s)-3-메톡시-4-(메틸아미노)-1-피롤리딘일]-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카복실산의 제조 방법
|
|
PE20120008A1
(es)
|
2009-01-12 |
2012-01-24 |
Icagen Inc |
Derivados de fenoxi bencenosulfonamida
|
|
WO2010082813A1
(en)
|
2009-01-13 |
2010-07-22 |
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam |
Method of treating cancer
|
|
CA2749278A1
(en)
|
2009-01-14 |
2010-07-22 |
Novacta Biosystems Limited |
Deoxyactagardine derivatives
|
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
|
CN102388060B
(zh)
|
2009-02-04 |
2014-09-10 |
诺瓦克塔生物系统有限公司 |
阿肽加定衍生物
|
|
EP2395995A1
(de)
|
2009-02-10 |
2011-12-21 |
Celgene Corporation |
Anwendungsverfahren und zusammensetzungen mit pde4-modulatoren zur behandlung, prävention und management von tuberkulose
|
|
BRPI1008020A2
(pt)
|
2009-02-11 |
2016-03-15 |
Sunovion Pharmaceuticals Inc |
antagonistas e agonistas inversos h3 da histamina e métodos de uso dos mesmos
|
|
US20120053159A1
(en)
|
2009-02-11 |
2012-03-01 |
Muller George W |
Isotopologues of lenalidomide
|
|
WO2010099526A1
(en)
|
2009-02-27 |
2010-09-02 |
Sunesis Pharmaceuticals, Inc. |
Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
|
|
CN102369212B
(zh)
|
2009-03-12 |
2015-12-16 |
哈瑟投资公司 |
具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体
|
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
|
EP2233502A1
(de)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
|
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
|
SG175207A1
(en)
|
2009-04-14 |
2011-11-28 |
Lilly Co Eli |
Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
|
|
CA2761455C
(en)
|
2009-05-13 |
2018-06-12 |
Cydex Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
|
|
EP2436387B1
(de)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmazeutische zusammensetzung enthaltend crbn zur verwendung in der behandlung von krankeiten des cerebralen cortex.
|
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
|
CA2760284A1
(en)
|
2009-05-29 |
2010-12-02 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
|
PL2434886T3
(pl)
*
|
2009-05-29 |
2020-05-18 |
Cydex Pharmaceuticals, Inc. |
Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania
|
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
|
SG176735A1
(en)
|
2009-06-10 |
2012-01-30 |
Sunovion Pharmaceuticals Inc |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
|
EP2266563A1
(de)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
RU2012102259A
(ru)
|
2009-06-24 |
2013-07-27 |
Стефен ЭВАНС-ФРИК |
Способы применения кортикотропин-рилизинг фактора для лечения рака
|
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
DE102009034368A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
|
ES2573982T3
(es)
|
2009-08-19 |
2016-06-13 |
Ratiopharm Gmbh |
Proceso para la producción de coevaporados y complejos que comprenden voriconazol y ciclodextrina
|
|
MX2012002898A
(es)
|
2009-09-11 |
2012-04-02 |
Sunovion Pharmaceuticals Inc |
Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
|
|
WO2011041593A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
|
EP2499248B1
(de)
|
2009-11-13 |
2017-01-04 |
Sarepta Therapeutics, Inc. |
Antivirale antisense-verbindung und verfahren zur behandlung von influenzavirusinfektion
|
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
|
US20140004182A1
(en)
|
2009-11-19 |
2014-01-02 |
Jerome B. Zeldis |
Methods for the treatment of sarcoidosis
|
|
WO2011064558A2
(en)
|
2009-11-30 |
2011-06-03 |
Cipla Limited |
Pharmaceutical composition
|
|
SG10201510665WA
(en)
|
2009-12-04 |
2016-01-28 |
Sunovion Pharmaceuticals Inc |
Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
|
|
US8772301B2
(en)
|
2009-12-18 |
2014-07-08 |
Sunovion Pharmaceuticals, Inc. |
Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
|
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
|
BR112012015129A2
(pt)
|
2009-12-22 |
2019-09-24 |
Celgene Corp |
"composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
|
|
NZ601267A
(en)
|
2009-12-23 |
2014-03-28 |
Takeda Pharmaceutical |
Fused heteroaromatic pyrrolidinones as syk inhibitors
|
|
MX337566B
(es)
|
2010-01-05 |
2016-03-10 |
Celgene Corp |
Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
|
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
|
CA2789164A1
(en)
|
2010-02-02 |
2011-08-11 |
Novacta Biosystems Limited |
Lantibiotic salts
|
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
|
PL3202460T3
(pl)
|
2010-02-11 |
2019-12-31 |
Celgene Corporation |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
WO2011104649A1
(en)
|
2010-02-25 |
2011-09-01 |
Pfizer Limited |
Peptide analogues
|
|
EP2542238B1
(de)
|
2010-03-01 |
2015-08-12 |
Onyx Therapeutics, Inc. |
Verbindungen zur immunproteasomhemmung
|
|
KR20130038838A
(ko)
|
2010-03-12 |
2013-04-18 |
셀진 코포레이션 |
레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
|
|
US9068185B2
(en)
|
2010-03-12 |
2015-06-30 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
|
NZ602872A
(en)
|
2010-04-07 |
2014-05-30 |
Onyx Therapeutics Inc |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
US8916593B2
(en)
|
2010-05-04 |
2014-12-23 |
Pfizer Inc. |
Alkoxy-substituted 2-aminopyridines as ALK inhibitors
|
|
CA3090304A1
(en)
|
2010-05-13 |
2011-11-17 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
|
US8969349B2
(en)
|
2010-05-26 |
2015-03-03 |
Sunovion Pharmaceuticals Inc. |
Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
|
|
MX338405B
(es)
|
2010-05-26 |
2016-04-14 |
Neurophyxia B V |
Formulaciones de 2-iminobiotina y sus usos.
|
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
WO2011163612A1
(en)
|
2010-06-24 |
2011-12-29 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
|
US8450316B2
(en)
|
2010-06-24 |
2013-05-28 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
|
MX338685B
(es)
|
2010-06-29 |
2016-04-26 |
Merck Sharp & Dohme |
Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida.
|
|
NL2005052C2
(en)
|
2010-07-07 |
2012-01-10 |
Caroline Haaften |
Xanthanodien for the treatment of cancer.
|
|
ES2526675T3
(es)
|
2010-07-09 |
2015-01-14 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
|
|
JP5872552B2
(ja)
|
2010-07-09 |
2016-03-01 |
ファイザー・リミテッドPfizer Limited |
化学化合物
|
|
CA2804593C
(en)
|
2010-07-09 |
2015-11-24 |
Pfizer Limited |
Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
|
|
JP2013536165A
(ja)
|
2010-07-12 |
2013-09-19 |
ファイザー・リミテッド |
痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
|
|
JP2013532184A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネル阻害剤として有用なn−スルホニルベンズアミド誘導体
|
|
CA2804351A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
|
JP2013532185A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
化合物
|
|
JP2013531030A
(ja)
|
2010-07-12 |
2013-08-01 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネルの阻害剤としてのn−スルホニルベンズアミド
|
|
EP2409699B1
(de)
|
2010-07-23 |
2014-04-30 |
Combino Pharm, S.L. |
Stabile Voriconazole-enthaltende Zusammensetzungen
|
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
|
EP2609105B1
(de)
|
2010-08-24 |
2016-03-09 |
Imperial Innovations Limited |
Glycodendrimere aus polypropyletheriminen
|
|
JP5820476B2
(ja)
|
2010-08-24 |
2015-11-24 |
アルギアックス ファルマコウティカルス ゲーエムベーハーALGIAX Pharmaceuticals GmbH |
レフルノミドおよびマロノニトリラマイドの新規の使用
|
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
|
PT2632451T
(pt)
|
2010-10-29 |
2017-12-14 |
Algiax Pharmaceuticals Gmbh |
Utilização de malononitrilamidas na dor neuropática
|
|
EP2635273B1
(de)
|
2010-11-01 |
2020-01-08 |
MEI Pharma, Inc. |
Isoflavonoidzusammensetzungen und verfahren zur krebsbehandlung
|
|
EP2640729B1
(de)
|
2010-11-15 |
2016-12-21 |
VIIV Healthcare UK Limited |
Hiv-replikationshemmer
|
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
|
EP2663549B1
(de)
|
2011-01-10 |
2018-03-14 |
Celgene Corporation |
Phenethylsulfonisoindolinderivate als pde-4- und/oder zytokin-hemmer
|
|
US8765760B2
(en)
|
2011-01-11 |
2014-07-01 |
Sunovion Pharmaceuticals, Inc. |
[1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
|
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
|
WO2012097116A2
(en)
|
2011-01-14 |
2012-07-19 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
|
US10463687B2
(en)
|
2011-01-20 |
2019-11-05 |
Cornell University |
Treatments for retinal disorders
|
|
KR101914940B1
(ko)
|
2011-01-26 |
2018-11-06 |
알러간, 인코포레이티드 |
안과 질환을 치료하기 위한 안드로겐 조성물
|
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
|
US8791107B2
(en)
|
2011-02-25 |
2014-07-29 |
Takeda Pharmaceutical Company Limited |
N-substituted oxazinopteridines and oxazinopteridinones
|
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
|
WO2012120365A1
(en)
|
2011-03-07 |
2012-09-13 |
Aurobindo Pharma Limited |
Stable pharmaceutical composition comprising ethinyl estradiol
|
|
PH12013501837A1
(en)
|
2011-03-11 |
2013-11-18 |
Celgene Corp |
Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
|
|
DK2683708T3
(da)
|
2011-03-11 |
2018-01-29 |
Celgene Corp |
Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
|
|
US20140057978A1
(en)
|
2011-03-17 |
2014-02-27 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
|
EP2685983B1
(de)
|
2011-03-17 |
2016-05-18 |
Algiax Pharmaceuticals GmbH |
Neue verwendung von imidazotriazinonen
|
|
EP2699091B1
(de)
|
2011-03-28 |
2017-06-21 |
DeuteRx, LLC |
2',6'-dioxo-3'-deutero-piperidin-3-yl-isoindolin-verbindungen
|
|
RU2464042C1
(ru)
*
|
2011-03-31 |
2012-10-20 |
Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" |
КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
|
|
PH12013502020A1
(en)
|
2011-04-05 |
2018-04-11 |
Pfizer Ltd |
Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
|
|
WO2012138214A1
(en)
|
2011-04-08 |
2012-10-11 |
Brewster Lizzy Maritza |
Beta-guanidinopropionic acid for the treatment of hypertension
|
|
AU2012249491B2
(en)
|
2011-04-29 |
2016-12-15 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
WO2012157288A1
(en)
|
2011-05-18 |
2012-11-22 |
Raqualia Pharma Inc. |
Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
|
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
|
WO2012163546A1
(en)
*
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
|
PL2720723T3
(pl)
|
2011-06-15 |
2018-10-31 |
Synthon Bv |
Stabilizowana kompozycja worykonazolu
|
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
|
EP2723739B1
(de)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituierte 6-aza-isoindolin-1-on-derivate
|
|
US9513253B2
(en)
|
2011-07-11 |
2016-12-06 |
Advanced Liquid Logic, Inc. |
Droplet actuators and techniques for droplet-based enzymatic assays
|
|
EP2731959B1
(de)
|
2011-07-13 |
2016-02-03 |
Pfizer Limited |
Enkephalinanaloga
|
|
US10100305B2
(en)
|
2011-07-15 |
2018-10-16 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation of start sites
|
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
|
RU2014102935A
(ru)
|
2011-08-02 |
2015-09-10 |
Пфайзер Инк. |
Кризотиниб для применения в лечении рака
|
|
WO2013017136A1
(en)
|
2011-08-02 |
2013-02-07 |
Pensieve Biosciences Cyprus Limited |
Treatment of cognitive impairment
|
|
EP2561863A1
(de)
|
2011-08-22 |
2013-02-27 |
Farmaprojects, S.A.U. |
Pharmazeutische Zusammensetzungen mit Voriconazol
|
|
DK2758052T3
(en)
|
2011-09-18 |
2018-05-28 |
Euro Celtique Sa |
Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
|
|
WO2013043985A1
(en)
|
2011-09-23 |
2013-03-28 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
|
CA2850925C
(en)
|
2011-10-26 |
2017-01-10 |
Pfizer Limited |
(4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
|
|
WO2013061297A1
(en)
|
2011-10-28 |
2013-05-02 |
Pfizer Limited |
Pyridazine Derivatives Useful in Therapy
|
|
ES2935606T3
(es)
|
2011-12-08 |
2023-03-08 |
Sarepta Therapeutics Inc |
Análogos de oligonucleótidos dirigidos a LMNA humana
|
|
WO2013088315A1
(en)
|
2011-12-15 |
2013-06-20 |
Pfizer Limited |
Sulfonamide derivatives
|
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
|
EP2794592A1
(de)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
|
|
WO2013096051A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
EP2794591A1
(de)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
|
|
US9126980B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
BR112014015308A8
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com contrapartes de ligação
|
|
TW201332572A
(zh)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
具有經取代的β-環糊精之藥物製劑
|
|
US20150291514A1
(en)
|
2012-01-04 |
2015-10-15 |
Pfizer Limted |
N-Aminosulfonyl Benzamides
|
|
EP2806877B2
(de)
|
2012-01-23 |
2025-01-29 |
Sage Therapeutics, Inc. |
Neuroaktive steroid-formulierungen mit einem komplex aus allopregnanolon und sulfobutylether beta-cyclodextrin
|
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
|
TWI573792B
(zh)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
|
JP6002785B2
(ja)
|
2012-02-03 |
2016-10-05 |
ファイザー・インク |
ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
|
|
WO2013119895A1
(en)
|
2012-02-08 |
2013-08-15 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
|
TW201336527A
(zh)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
|
WO2013123254A1
(en)
|
2012-02-15 |
2013-08-22 |
Cydex Pharmaceuticals, Inc. |
Manufacturing process for cyclodextrin derivatives
|
|
WO2013126394A1
(en)
|
2012-02-21 |
2013-08-29 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
RU2615385C2
(ru)
*
|
2012-02-28 |
2017-04-04 |
Сидекс Фармасьютикалс, Инк. |
Композиции алкилированного циклодекстрина и способы их получения и применения
|
|
US20150099012A1
(en)
|
2012-03-02 |
2015-04-09 |
Erasmus University Medical Center Rotterdam |
Methods for activating retrovirus in latent infected cells, and compounds for use therein
|
|
DK2822953T5
(en)
|
2012-03-06 |
2017-09-11 |
Pfizer |
Macrocyclic derivatives for the treatment of proliferative diseases
|
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
|
ES2620080T3
(es)
|
2012-03-30 |
2017-06-27 |
Sapiotec Gmbh |
Uso de delfinidina contra Staphylococcus aureus
|
|
KR101905937B1
(ko)
|
2012-03-30 |
2018-10-08 |
자피오텍 게엠베하 |
안토시아니딘 복합체
|
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
|
CA2872958A1
(en)
|
2012-05-11 |
2013-11-14 |
Cipla Limited |
Pharmaceutical composition
|
|
WO2013171642A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
|
PE20161416A1
(es)
|
2012-05-15 |
2017-01-08 |
Novartis Ag |
Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
|
|
CA2870339C
(en)
|
2012-05-15 |
2020-06-02 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
|
|
CN104379574B
(zh)
|
2012-05-15 |
2017-03-01 |
诺华股份有限公司 |
用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
|
|
WO2013183985A1
(en)
|
2012-06-05 |
2013-12-12 |
Erasmus University Medical Center Rotterdam |
Method of treating cognitive impairment and compounds for use therein
|
|
ES2872967T3
(es)
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
|
US20140105921A1
(en)
|
2012-07-09 |
2014-04-17 |
Onyx Therapeutics, Inc. |
Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
|
|
TW201414734A
(zh)
|
2012-07-10 |
2014-04-16 |
Takeda Pharmaceutical |
氮雜吲哚衍生物
|
|
EP2874605A1
(de)
|
2012-07-18 |
2015-05-27 |
Onyx Therapeutics, Inc. |
Liposomale zusammensetzungen von proteasomhemmern auf epoxyketonbasis
|
|
LT2882441T
(lt)
|
2012-08-09 |
2020-07-27 |
Celgene Corporation |
Su imunitetu susijusių ir uždegiminių ligų gydymas
|
|
ES2885769T3
(es)
|
2012-08-09 |
2021-12-15 |
Celgene Corp |
Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
|
|
AU2013299627C1
(en)
|
2012-08-09 |
2018-05-31 |
Celgene Corporation |
Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
CA2882708A1
(en)
|
2012-08-21 |
2014-02-27 |
Sage Therapeutics, Inc. |
Methods of treating epilepsy or status epilepticus
|
|
US9655977B2
(en)
|
2012-08-31 |
2017-05-23 |
The General Hospital Corporation |
Biotin complexes for treatment and diagnosis of alzheimer's disease
|
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
|
EP2892537A1
(de)
|
2012-09-10 |
2015-07-15 |
Celgene Corporation |
Verfahren zur behandlung von lokal fortgeschrittenem brustkrebs
|
|
WO2014045029A1
(en)
|
2012-09-18 |
2014-03-27 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
|
|
CA2884848C
(en)
|
2012-09-28 |
2017-08-22 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
|
US20150218172A1
(en)
|
2012-10-04 |
2015-08-06 |
Pfizer Limited |
Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
|
|
JP2015531395A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
ピロロ[3,2−c]ピリジントロポミオシン関連キナーゼ阻害剤
|
|
JP2015531393A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
トロポミオシン関連キナーゼ阻害剤
|
|
KR102112119B1
(ko)
|
2012-10-22 |
2020-05-19 |
사이덱스 파마슈티칼스, 인크. |
알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
|
|
AU2013343105B2
(en)
|
2012-11-08 |
2016-04-14 |
Pfizer Inc. |
Heteroaromatic compounds as dopamine D1 ligands
|
|
CA2890009C
(en)
|
2012-11-08 |
2017-11-28 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
JP2015536991A
(ja)
|
2012-11-09 |
2015-12-24 |
セルジーン コーポレイション |
骨量の減少の治療方法
|
|
WO2014075935A1
(de)
|
2012-11-15 |
2014-05-22 |
Sapiotec Gmbh |
Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
|
|
BR112015011392A2
(pt)
|
2012-11-21 |
2017-07-11 |
Raqualia Pharma Inc |
formas polimórficas de ácidos, processo de preparação, composição farmacêutica e uso das mesmas
|
|
AU2013352463B2
(en)
|
2012-11-29 |
2017-06-15 |
Sunovion Pharmaceuticals Inc. |
Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
|
|
AU2013352141B2
(en)
|
2012-11-30 |
2018-04-05 |
The Regents Of The University Of California |
Anticonvulsant activity of steroids
|
|
DK2925725T3
(en)
|
2012-12-03 |
2017-01-16 |
Pfizer |
androgen receptor modulators
|
|
CN104936601A
(zh)
|
2012-12-11 |
2015-09-23 |
赛博尔泰克股份公司 |
用于对抗黑色素瘤细胞的飞燕草素
|
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
|
HK1216902A1
(zh)
|
2012-12-20 |
2016-12-09 |
Sarepta Therapeutics, Inc. |
用作治疗肌肉萎缩的改进外显子跳跃组合物
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
WO2014106238A1
(en)
|
2012-12-31 |
2014-07-03 |
Fang, Qun, Kevin |
Heterocyclic compounds and methods of use thereof
|
|
JP6359563B2
(ja)
|
2013-01-14 |
2018-07-18 |
デュートルクス・リミテッド・ライアビリティ・カンパニーDeuteRx, LLC |
3−(5置換−4−オキソキナゾリン−3(4h)−イル)−3−ジュウテロピペリジン−2,6−ジオン誘導体
|
|
WO2014116573A1
(en)
|
2013-01-22 |
2014-07-31 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
|
ES2671516T3
(es)
|
2013-02-19 |
2018-06-06 |
Novartis Ag |
Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
|
|
MX386473B
(es)
|
2013-02-21 |
2025-03-18 |
Pfizer |
Formas solidas de un inhibidor de cdk4/6 selectivo
|
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
|
US20140315977A1
(en)
|
2013-03-14 |
2014-10-23 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
CN110218727A
(zh)
|
2013-03-14 |
2019-09-10 |
萨勒普塔医疗公司 |
用于治疗肌营养不良的外显子跳跃组合物
|
|
JP6649246B2
(ja)
*
|
2013-03-14 |
2020-02-19 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法
|
|
US20140329762A1
(en)
|
2013-03-15 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
EP2784083A1
(de)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
|
|
BR112015025252A2
(pt)
|
2013-04-02 |
2017-07-18 |
Celgene Corp |
métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
|
|
EP2792360A1
(de)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
|
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
|
EP2815749A1
(de)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
|
|
DK3013813T3
(da)
|
2013-06-27 |
2019-06-03 |
Pfizer |
Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander
|
|
US9364458B2
(en)
|
2013-07-08 |
2016-06-14 |
Abbvie Inc. |
Stabilized pharmaceutical dosage forms comprising atrasentan
|
|
GB201312737D0
(en)
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
EP3083602A1
(de)
|
2013-12-20 |
2016-10-26 |
Pfizer Limited |
N-acylpiperidin-ether-tropomyosin-vermittelte kinasehemmer
|
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
|
WO2015106012A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
|
CN103694376B
(zh)
*
|
2014-01-10 |
2016-04-13 |
凯莱英医药集团(天津)股份有限公司 |
一种制备磺丁基醚-β-环糊精的方法
|
|
EP3094328B1
(de)
|
2014-01-15 |
2020-08-19 |
Poxel SA |
Verfahren zur behandlung von neurologischen, stoffwechsel- und anderen erkrankungen mit enantiomerenreinem deuterium-angereicherten pioglitazon
|
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
|
EP2913050A1
(de)
|
2014-02-28 |
2015-09-02 |
SapioTec GmbH |
Verfahren zur Herstellung eines Flurankomplexes
|
|
AU2015233686B2
(en)
|
2014-03-18 |
2019-07-11 |
Algiax Pharmaceuticals Gmbh |
2-Cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives
|
|
WO2015159175A1
(en)
|
2014-04-15 |
2015-10-22 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
|
|
EP3134405B1
(de)
|
2014-04-25 |
2019-08-28 |
Pfizer Inc |
Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
|
|
AU2015249497A1
(en)
|
2014-04-25 |
2016-10-20 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
|
WO2015162515A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
EP3137454A1
(de)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
|
|
CA2946990A1
(en)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Heterocyclic compounds and their use as dopamine d1 ligands
|
|
EP3139924A4
(de)
|
2014-05-06 |
2018-03-07 |
Anthony G. Visco |
Verfahren zur behandlung oder prävention von vorzeitigen wehen
|
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
|
KR20170002623A
(ko)
|
2014-05-14 |
2017-01-06 |
화이자 인코포레이티드 |
피라졸로피리딘 및 피라졸로피리미딘
|
|
SG11201608320QA
(en)
|
2014-05-15 |
2016-11-29 |
Pfizer |
Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
|
|
CA2944982C
(en)
|
2014-05-20 |
2022-06-07 |
Raqualia Pharma Inc. |
Benzisoxazole derivative salt
|
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
ES2864079T3
(es)
|
2014-05-30 |
2021-10-13 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
|
|
CA2950393A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
|
CA2951497C
(en)
|
2014-06-12 |
2019-04-09 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the gabaa receptor activity
|
|
TN2016000529A1
(en)
|
2014-06-17 |
2018-04-04 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
|
JP6276429B2
(ja)
|
2014-06-18 |
2018-02-07 |
イーライ リリー アンド カンパニー |
ペルゴリドの経皮製剤およびその使用
|
|
EP3827836A1
(de)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Zusammensetzungen und verfahren zur induktion von konformationsänderungen bei cereblon und anderen e3-ubiquitin-ligasen
|
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
|
TWI568365B
(zh)
*
|
2014-07-22 |
2017-02-01 |
蘇廷弘 |
抑菌複合物及其製造方法
|
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
|
PT3183295T
(pt)
|
2014-08-22 |
2023-11-03 |
Cydex Pharmaceuticals Inc |
Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
|
|
AU2015305449B2
(en)
|
2014-08-22 |
2021-05-06 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
WO2016044433A2
(en)
|
2014-09-16 |
2016-03-24 |
Biopharma Works |
Metformin derivatives
|
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用
|
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
|
DK3247371T3
(da)
|
2015-01-22 |
2020-06-15 |
Phytoplant Res S L |
Fremgangsmåder til oprensning af cannabinoider, sammensætninger og kits dertil
|
|
ES2764840T3
(es)
|
2015-01-28 |
2020-06-04 |
Univ Bordeaux |
Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
|
|
CN116139125A
(zh)
|
2015-02-02 |
2023-05-23 |
梅制药公司 |
联合治疗
|
|
CA2973140C
(en)
|
2015-02-06 |
2025-09-16 |
Marinus Pharmaceuticals, Inc. |
Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders
|
|
MX2017010844A
(es)
|
2015-02-24 |
2017-12-07 |
Pfizer |
Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
|
|
WO2016148674A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates for treating diseases
|
|
CA2980170A1
(en)
|
2015-03-19 |
2016-09-22 |
Cydex Pharmaceuticals, Inc. |
Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
|
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
|
NL2014614B1
(en)
|
2015-04-10 |
2017-01-25 |
Pld Biochemistry B V |
Method and means for increasing antibodies against Borrelia burgdorferi and increasing antigen of Borrelia burgdorferi.
|
|
WO2016195476A1
(en)
|
2015-05-29 |
2016-12-08 |
Erasmus University Medical Center Rotterdam |
Treatment of cardiac arrhythmias
|
|
WO2016203405A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
EP3310779B1
(de)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Verbindungen und zusammensetzungen zur hemmung der aktivität von shp2
|
|
US10287266B2
(en)
|
2015-06-19 |
2019-05-14 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
|
HUE065109T2
(hu)
|
2015-06-26 |
2024-05-28 |
Celgene Corp |
Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
|
|
US10973822B2
(en)
|
2015-07-02 |
2021-04-13 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
|
WO2017007805A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences, Inc. |
Intravenous formulations of a late sodium current inhibitor
|
|
UA121775C2
(uk)
|
2015-07-31 |
2020-07-27 |
Пфайзер Інк. |
1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
|
|
WO2017059131A1
(en)
|
2015-09-30 |
2017-04-06 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
BR112018011138A2
(pt)
|
2015-11-30 |
2018-11-21 |
Glaxosmithkline Intellectual Property (No. |
formulações para administração intravenosa
|
|
EP3386983A1
(de)
|
2015-12-10 |
2018-10-17 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazin-derivate der formel (i) als gaba-rezeptormodulatoren zur verwendung bei der behandlung von epilepsie und schmerzen
|
|
EA039213B1
(ru)
|
2015-12-24 |
2021-12-17 |
Такеда Фармасьютикал Компани Лимитед |
Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
|
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
|
TWI726968B
(zh)
|
2016-01-07 |
2021-05-11 |
開曼群島商Cs醫藥技術公司 |
Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
|
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
|
CA3011201C
(en)
|
2016-01-15 |
2020-09-22 |
Pfizer Inc. |
6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
|
|
EP4098282A1
(de)
*
|
2016-02-04 |
2022-12-07 |
Czap Research And Development, LLC |
Trägerstoffe mit kontrollierter freisetzung und stratifiziertem cyclodextrineinschlusskomplex
|
|
KR20240157128A
(ko)
|
2016-03-08 |
2024-10-31 |
세이지 테라퓨틱스, 인크. |
신경활성 스테로이드, 조성물, 및 그의 용도
|
|
US11753626B2
(en)
|
2016-03-09 |
2023-09-12 |
Beijing Percans Oncology Co., Ltd. |
Tumor cell suspension cultures and related methods
|
|
DK3436447T3
(da)
*
|
2016-03-31 |
2021-09-13 |
Takeda Pharmaceuticals Co |
Isoquinolinyl-triazolon-komplekser
|
|
MX2018013157A
(es)
|
2016-04-29 |
2019-05-23 |
Sarepta Therapeutics Inc |
Analogos de oligonucleotidos dirigidos a lmna humana.
|
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
|
WO2017216706A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
JP2019525742A
(ja)
|
2016-06-30 |
2019-09-12 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーに対するエクソンスキッピングオリゴマー
|
|
EP3487508B1
(de)
*
|
2016-07-22 |
2023-09-13 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Viruzidverbindungen und verwendungen davon
|
|
US20190270778A1
(en)
|
2016-07-29 |
2019-09-05 |
Pfizer Inc. |
Cyclic Peptides As C5a Receptor Antagonists
|
|
MA45795A
(fr)
|
2016-07-29 |
2019-06-05 |
Sunovion Pharmaceuticals Inc |
Composés et compositions, et utilisations associées
|
|
PT3494119T
(pt)
|
2016-07-29 |
2024-12-10 |
Pgi Drug Discovery Llc |
Compostos e composições e seus usos
|
|
EP3481387A4
(de)
|
2016-08-11 |
2020-04-08 |
Ovid Therapeutics Inc |
Verfahren und zusammensetzungen zur behandlung von epileptischen erkrankungen
|
|
PT3497103T
(pt)
|
2016-08-15 |
2021-06-17 |
Pfizer |
Inibidores de piridopirimidinona cdk2/4/6
|
|
US10532102B2
(en)
|
2016-08-19 |
2020-01-14 |
Foresee Pharmaceuticals Co., Ltd. |
Pharmaceutical composition and methods of uses
|
|
DK3503885T3
(da)
*
|
2016-08-19 |
2022-06-20 |
Foresee Pharmaceuticals Co Ltd |
Farmaceutisk præparat og fremgangsmåder til anvendelse heraf
|
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
|
AU2016426574B2
(en)
|
2016-10-11 |
2023-07-13 |
Euro-Celtique S.A. |
Hodgkin lymphoma therapy
|
|
CN110022857A
(zh)
|
2016-11-18 |
2019-07-16 |
艾库里斯抗感染治疗有限公司 |
基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
|
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
|
KR20240006023A
(ko)
|
2016-12-19 |
2024-01-12 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
PT3554552T
(pt)
|
2016-12-19 |
2022-10-03 |
Sarepta Therapeutics Inc |
Conjugados de oligómero de skipping de exão para distrofia muscular
|
|
KR102810425B1
(ko)
|
2016-12-19 |
2025-05-21 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
EP4252856A3
(de)
|
2016-12-20 |
2024-01-24 |
Oligomerix, Inc. |
Neuartige chinazolinone zur hemmung der bildung von tau-oligomeren und deren verfahren zur verwendung
|
|
EP3562483B1
(de)
|
2016-12-20 |
2025-09-03 |
Oligomerix, Inc. |
Neuartige benzofuran-, benzothiophen- und indolanaloga zur hemmung der bildung von tau-oligomeren und deren verwendung
|
|
EP3571191A1
(de)
|
2017-01-20 |
2019-11-27 |
Pfizer Inc |
1,1,1-trifluor-3-hydroxypropan-2-yl-carbamatderivate als magl-inhibitoren
|
|
EP3571202B1
(de)
|
2017-01-23 |
2021-06-30 |
Pfizer Inc. |
Heterocyclische spiro-verbindungen als magl-inhibitoren
|
|
WO2018140671A1
(en)
|
2017-01-27 |
2018-08-02 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
|
MX390141B
(es)
|
2017-02-16 |
2025-03-20 |
Sunovion Pharmaceuticals Inc |
Metodos para tratar esquizofrenia
|
|
JP7142675B2
(ja)
|
2017-03-26 |
2022-09-27 |
武田薬品工業株式会社 |
Gpr6のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド
|
|
CA3060514A1
(en)
|
2017-04-20 |
2018-10-25 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
|
JP7204670B2
(ja)
|
2017-05-03 |
2023-01-16 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
シクロデキストリン及びブスルファンを含有する組成物
|
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
|
UA125730C2
(uk)
|
2017-06-22 |
2022-05-25 |
Курадев Фарма Лімітед |
Низькомолекулярні модулятори sting людини
|
|
KR20200020899A
(ko)
*
|
2017-06-30 |
2020-02-26 |
셀진 코포레이션 |
2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법
|
|
WO2019014247A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
CA3070993C
(en)
|
2017-08-02 |
2025-05-20 |
Sunovion Pharmaceuticals Inc. |
ISOCHROMANE COMPOUNDS AND THEIR USES
|
|
MX2020002303A
(es)
|
2017-08-30 |
2020-09-10 |
Beijing Xuanyi Pharmasciences Co Ltd |
Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
|
|
JP7447002B2
(ja)
|
2017-09-11 |
2024-03-11 |
クルーゾン・ファーマシューティカルズ・インコーポレイテッド |
SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
|
WO2019067981A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
EP3687547A1
(de)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Kombinationstherapien zur behandlung von muskeldystrophie
|
|
WO2019067979A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
EP3746419A1
(de)
|
2018-01-29 |
2020-12-09 |
Phytoplant Research S.L. |
Verfahren zur reinigung von cannabinoiden unter verwendung von flüssig-flüssigchromatografie
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
|
US10538542B2
(en)
|
2018-03-15 |
2020-01-21 |
Pfizer Inc. |
Cyclopentane-based modulators of STING (stimulator of interferon genes)
|
|
GEP20227433B
(en)
|
2018-04-26 |
2022-10-25 |
Pfizer |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
|
US10758629B2
(en)
|
2018-05-29 |
2020-09-01 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
JP7541512B2
(ja)
|
2018-05-30 |
2024-08-28 |
コンバート ファーマシューティカルズ エス.エー. |
プロドラッグおよびその医学的使用
|
|
BR112020024301A2
(pt)
|
2018-06-01 |
2021-02-23 |
Bayer Cropscience Lp |
composição fungicida estabilizada compreendendo ciclodextrina
|
|
EP3806868A4
(de)
|
2018-06-13 |
2022-06-22 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomere für muskeldystrophie
|
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
|
AU2019304198A1
(en)
|
2018-07-19 |
2021-02-04 |
Pfizer Inc. |
Heterocyclic spiro compounds as MAGL inhibitors
|
|
JP7490925B2
(ja)
|
2018-07-26 |
2024-05-28 |
エータイアー ファーマ, インコーポレイテッド |
Nrp2関連疾患を治療するための組成物および方法
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
EP3846853A1
(de)
|
2018-09-04 |
2021-07-14 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Viruzide nanopartikel und verwendung davon gegen influenzavirus
|
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
|
AU2019387290A1
(en)
|
2018-11-29 |
2021-05-27 |
Pfizer Inc. |
Pyrazoles as modulators of hemoglobin
|
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
|
ES3041602T3
(en)
|
2018-12-10 |
2025-11-13 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
|
IL318474A
(en)
|
2018-12-13 |
2025-03-01 |
Sarepta Therapeutics Inc |
Axon-skipping oligomer complexes for muscular dystrophy
|
|
KR20210105380A
(ko)
|
2018-12-18 |
2021-08-26 |
먼디파머 인터내셔널 코포레이션 리미티드 |
다발성 골수종을 치료하기 위한 화합물
|
|
CN113490691A
(zh)
|
2019-01-03 |
2021-10-08 |
劣势者药物有限公司 |
环糊精二聚体、其组合物及其用途
|
|
US12397005B2
(en)
|
2019-01-04 |
2025-08-26 |
Sq Innovation Ag |
Pharmaceutical compositions of torsemide and uses thereof
|
|
US11246851B2
(en)
|
2019-01-04 |
2022-02-15 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
|
KR20210105955A
(ko)
|
2019-01-23 |
2021-08-27 |
화이자 인코포레이티드 |
공지된 테트라히드로이소퀴놀린 유도체의 모노포스페이트 수화물 염의 다형체 형태
|
|
IL284589B2
(en)
|
2019-01-31 |
2025-10-01 |
Pfizer |
3–Carbonylamino–5–cyclopentyl–h1–pyrazole compounds with cdk2 inhibitory activity
|
|
US11529357B2
(en)
|
2019-02-01 |
2022-12-20 |
H. Lundbeck A/S |
Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
|
|
EP3938045A1
(de)
|
2019-03-14 |
2022-01-19 |
Sunovion Pharmaceuticals Inc. |
Salze einer isochromanylverbindung und kristalline formen, verfahren zur herstellung, therapeutische verwendungen und pharmazeutische zusammensetzungen davon
|
|
WO2020198053A1
(en)
|
2019-03-22 |
2020-10-01 |
Takeda Pharmaceutical Company Limited |
2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
|
|
US20220152086A1
(en)
|
2019-03-28 |
2022-05-19 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy with casimersen
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
MX2021013135A
(es)
|
2019-04-29 |
2021-11-25 |
Solent Therapeutics Llc |
Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
|
|
JP2022536495A
(ja)
|
2019-06-19 |
2022-08-17 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを治療する方法
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
JP7691974B2
(ja)
|
2019-07-25 |
2025-06-12 |
キュラデブ ファーマ ピーブイティー. リミテッド |
アセチル補酵素aシンテターゼ短鎖2(acss2)の小分子阻害剤
|
|
JP7754799B2
(ja)
|
2019-08-05 |
2025-10-15 |
マリナス ファーマシューティカルズ, インコーポレイテッド |
てんかん重積状態の治療に使用するためのガナキソロン
|
|
US20230000997A1
(en)
|
2019-08-06 |
2023-01-05 |
L.E.A.F. Holdings Group Llc |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
|
CR20220160A
(es)
|
2019-09-16 |
2022-06-16 |
Takeda Pharmaceuticals Co |
Derivados de piridazin-3(2h)-ona fusionados con azol
|
|
KR20220070254A
(ko)
|
2019-09-25 |
2022-05-30 |
화이자 인코포레이티드 |
Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제
|
|
US20210145816A1
(en)
|
2019-11-15 |
2021-05-20 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
|
|
WO2021113212A1
(en)
|
2019-12-02 |
2021-06-10 |
Celgene Corporation |
Therapy for the treatment of cancer
|
|
WO2021113834A1
(en)
|
2019-12-06 |
2021-06-10 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating tuberous sclerosis complex
|
|
CA3166358A1
(en)
|
2020-02-12 |
2021-08-19 |
Monali BANERJEE |
Small molecule sting antagonists
|
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
|
PE20230323A1
(es)
|
2020-05-01 |
2023-02-22 |
Pfizer |
Compuestos de azalactama como inhibidores de hpk1
|
|
BR112022022184A2
(pt)
|
2020-05-04 |
2023-01-17 |
Takeda Pharmaceuticals Co |
Derivados de n-(piperidin-4-il)benzamida agindo luminalmente
|
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
|
CN119285527A
(zh)
|
2020-06-30 |
2025-01-10 |
瑞安神经科学公司 |
色胺前药
|
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
|
CA3195121A1
(en)
|
2020-10-09 |
2022-04-14 |
Robert A. Volkmann |
Heteroaryl amide inhibitors of cd38
|
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
|
EP4313151A1
(de)
|
2021-03-31 |
2024-02-07 |
Sevenless Therapeutics Limited |
Sos1-inhibitoren und ras-inhibitoren zur verwendung bei der behandlung von schmerzen
|
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
|
US20240208934A1
(en)
|
2021-04-07 |
2024-06-27 |
Lifearc |
Ulk1/2 inhibitors and their use thereof
|
|
CR20230604A
(es)
|
2021-06-26 |
2024-02-19 |
Array Biopharma Inc |
Inhibidores de mutación de her2
|
|
US20240391931A1
(en)
|
2021-08-05 |
2024-11-28 |
Bristol-Myers Squibb Company |
Tricyclic fused pyrimidine compounds for use as her2 inhibitors
|
|
AU2022326885A1
(en)
|
2021-08-11 |
2024-02-15 |
Curadev Pharma Pvt. Ltd. |
Small molecule urea derivatives as sting antagonists
|
|
WO2023017451A1
(en)
|
2021-08-11 |
2023-02-16 |
Curadev Pharma Pvt. Ltd. |
Small molecule sting antagonists
|
|
EP4162933A1
(de)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Verbindung zur behandlung von nicht-alkoholischer fettlebererkrankung und verwandten erkrankungen
|
|
US20250042918A1
(en)
|
2021-12-01 |
2025-02-06 |
Fundación Del Sector Públlco Estatal Centro Nacional De Investigaciones Oncológicas Carlos III |
Compounds
|
|
CN119013401A
(zh)
|
2022-03-17 |
2024-11-22 |
萨勒普塔医疗公司 |
二氨基磷酸酯吗啉代寡聚物缀合物
|
|
KR20240169050A
(ko)
|
2022-03-30 |
2024-12-02 |
다케다 야쿠힌 고교 가부시키가이샤 |
N-(피롤리딘-3-일 또는 피페리딘-4-일)아세트아마이드 유도체
|
|
AR129012A1
(es)
|
2022-04-07 |
2024-07-03 |
Takeda Pharmaceuticals Co |
Derivados de piridazina fusionados
|
|
MA71611A
(fr)
|
2022-07-29 |
2025-05-30 |
Pfizer Inc. |
Nouveaux inhibiteurs de l'acc
|
|
JP2025526692A
(ja)
|
2022-08-10 |
2025-08-15 |
武田薬品工業株式会社 |
複素環式化合物
|
|
KR20250099462A
(ko)
|
2022-09-28 |
2025-07-01 |
알토스 랩스, 인크. |
노화된 세포/노화 세포에서의 재생 인자의 발현
|
|
EP4598538A1
(de)
|
2022-10-05 |
2025-08-13 |
Sevenless Therapeutics Limited |
Neue schmerzbehandlungen
|
|
CN120513245A
(zh)
|
2022-11-15 |
2025-08-19 |
克拉德夫制药有限公司 |
造血前驱细胞激酶1的吡啶酮及嘧啶酮抑制剂
|
|
AU2023420130A1
(en)
|
2022-12-30 |
2025-08-14 |
Cornell University |
Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
|
|
KR20250135317A
(ko)
|
2023-01-26 |
2025-09-12 |
다케다 야쿠힌 고교 가부시키가이샤 |
신경퇴행성 질환의 치료에 유용한 1-아미노-4-페닐프탈라진 유도체
|
|
KR20250170647A
(ko)
|
2023-04-14 |
2025-12-05 |
다케다 야쿠힌 고교 가부시키가이샤 |
Nlrp3 억제제로서의 피라졸로피리미딘 유도체
|
|
EP4705341A1
(de)
|
2023-05-05 |
2026-03-11 |
Euro-Celtique S.A. |
Kombinationen zur behandlung von krebs
|
|
GB2631397A
(en)
|
2023-06-28 |
2025-01-08 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
GB2633813A
(en)
|
2023-09-21 |
2025-03-26 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
WO2025074305A1
(en)
|
2023-10-04 |
2025-04-10 |
Takeda Pharmaceutical Company Limited |
N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
|
|
WO2025083426A1
(en)
|
2023-10-20 |
2025-04-24 |
Sevenless Therapeutics Limited |
New treatments for pain
|
|
GB202319181D0
(en)
|
2023-12-14 |
2024-01-31 |
Imperial College Innovations Ltd |
Nora Inhibitors
|
|
WO2025137437A1
(en)
|
2023-12-21 |
2025-06-26 |
Pfizer Inc. |
Solid forms of a gabaa receptor modulator and methods of its use
|
|
WO2025146548A1
(en)
|
2024-01-04 |
2025-07-10 |
Sevenless Therapeutics Limited |
Sos1 inhibitors useful to treat pain and cancer
|
|
WO2025229624A2
(en)
|
2024-05-02 |
2025-11-06 |
Napa Therapeutics Limited |
New cd38 inhibitors
|
|
WO2025231370A1
(en)
|
2024-05-02 |
2025-11-06 |
Napa Therapeutics Limited |
Inhibitors of cd38
|
|
WO2025233837A1
(en)
|
2024-05-07 |
2025-11-13 |
Takeda Pharmaceutical Company Limited |
4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder
|
|
US12383633B1
(en)
|
2024-10-01 |
2025-08-12 |
Zymeron Corporation |
Injectable formulations of PARP inhibitors and uses thereof
|
|
WO2026085322A1
(en)
|
2024-10-18 |
2026-04-23 |
Aardvark Therapeutics Inc. |
Isoflavonoid formulations and methods of use
|